TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21317777
Drug: Preincision intravenous
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision intravenous normal saline and direct infiltration of dexmedetomidine (1 μg/kg) to the surgical wounds at the end of the surgery (Group P)
Study: 21317777
Drug: Preincision intravenous
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision intravenous dexmedetomidine (1 mcg/kg) and direct infiltration of normal saline to the surgical wounds at the end of the surgery (Group D)
Study: 19571773
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid analysis
Study: 16179403
Drug: After 35-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 35-45 min of local cooling at BT + L-NAME sites
Study: 15750259
Drug: Valsartan (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (an angiotensin II receptor blocker)
Study: 11308252
Drug: Clodronate (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1.6 g daily orally) for 3 years
Study: 11308252
Drug: Antioestrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioestrogen therapy (tamoxifen 20 mg or toremifene 60 mg daily) for 3 years
Study: 9329386
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MK-677
Study: 9329386
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MK-677
Study: 3142943
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rt-PA intravenously over 3 h
Study: 31651213
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy (IPT) + Emotional Management Training (EMT)
Study: 25497473
Drug: bupropion-sustained-release+escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion-sustained-release+escitalopram
Study: 25497473
Drug: venlafaxine-extended-release+mirtazapine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine-extended-release+mirtazapine
Study: 23192403
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (nonobese)
Study: 23192403
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (obese)
Study: 23192403
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (nonobese)
Study: 23192403
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (obese)
Study: 23192403
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (both groups)
Study: 12857467
Drug: L-Arginine (L-Arg)
Normalized name: L-Arg
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (L-Arg) treatment
Study: 10365899
Drug: Pyloriset EIA‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloriset EIA‐G New (a quantitative enzyme‐linked immunosorbent assay)
Study: 8983917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acute exercise (E) + endurance training (T)
Study: 8983917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acute exercise (E) + endurance training (T) + selenium supplementation (Sel)
Study: 6294793
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g daily for 5-10 days, max 12 g in severe cases)
Study: 6294793
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g daily for 5-10 days)
Study: 6294793
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g daily for 5-10 days)
Study: 25622882
Drug: Intra-alveolar chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-alveolar chlorhexidine (CHX) gel
Study: 23250911
Drug: Adaptive servo-ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive servo-ventilation (ASV) combined with medications
Study: 10755201
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg)
Study: 10755201
Drug: Captopril (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (3 x 50 mg)
Study: 2021872
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) for 6 weeks
Study: 31338790
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention (Michael's game) alongside standard treatment for psychosis
Study: 31338790
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for psychosis
Study: 25134001
Drug: Glucose-fructose beverage
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-fructose beverage (1.55 g·min, 2:1 ratio)
Study: 25134001
Drug: Moderate-glucose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-glucose beverage (1.03 g·min)
Study: 25134001
Drug: High-glucose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose beverage (1.55 g·min)
Study: 15665657
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone supplementation (110 mg/day)
Study: 10193289
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg with Dexamethasone 8 mg
Study: 8594966
Drug: Lidocaine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (6 mg/kg body weight)
Study: 8594966
Drug: Prilocaine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (7 mg/kg body weight)
Study: 702289
Drug: Suspension A
Normalized name: KIT, SUSPENSION AND CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension A
Study: 702289
Drug: Suspension B
Normalized name: DROPS, SUSPENSION BIPHASIC RELEASE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension B (Control)
Study: 28007717
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of PUFA twice daily
Study: 21509675
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg per day) combined with Chinese medicine (CM) treatment for 12 weeks
Study: 21509675
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg per day) alone for 12 weeks
Study: 19538406
Drug: Natural childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural childbirth preparation with psychoprophylactic training (breathing and relaxation techniques)
Study: 19538406
Drug: Natural childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural childbirth preparation with psychoprophylactic training
Study: 9322446
Drug: Enoximone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.25 mg/kg bolus, cumulative dose 0.5 mg/kg)
Study: 8227480
Drug: Trandolapril 1
Normalized name: trandolapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 1 mg once daily
Study: 8227480
Drug: Trandolapril 0.5
Normalized name: trandolapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 0.5 mg twice daily
Study: 3510525
Drug: Diltiazem-SR 240
Normalized name: diltiazem hydrochloride 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-SR 240 mg/day
Study: 3510525
Drug: Diltiazem-SR 360
Normalized name: diltiazem hydrochloride 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-SR 360 mg/day
Study: 27344296
Drug: Radium-223 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (50 kBq/kg, intravenous injection) every 4 weeks for six cycles
Study: 24009292
Drug: Divided dosing
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dosing (BD) prednisolone
Study: 20211573
Drug: Sub-Tenon's ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's ropivacaine 1% (2.5-3 mL)
Study: 20211573
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (2.5-3 mL) in the control group
Study: 15715614
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg of Ringer's acetate over 3 min
Study: 15715614
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg of low‐molecular weight (1 kDa) dextran over 3 min
Study: 15715614
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg of Ringer's acetate over 40 min
Study: 11844036
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) treatment
Study: 7582386
Drug: Simvastatin 10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10‐40 mg once a day
Study: 2311339
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg administered orally) with food
Study: 30118728
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy with mometasone furoate (80% of students prescribed)
Study: 29437071
Drug: Three-monthly follow-up
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly follow-up group
Study: 29437071
Drug: Six-monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-monthly follow-up group
Study: 23173251
Drug: Danlou tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou tablet (DT) + Western medicine
Study: 23173251
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Control)
Study: 18020073
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg paracetamol
Study: 18020073
Drug: 90 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/kg paracetamol
Study: 15960557
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate 50/500 microg twice daily
Study: 10660874
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ENDUROX
Study: 10660874
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg placebo
Study: 373425
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment (5 patients)
Study: 373425
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (4 patients)
Study: 31494943
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular assist device (LVAD) therapy
Study: 27647855
Drug: TGF‐beta1 mAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF‐beta1 mAb (2‐, 10‐, or 50‐mg monthly subcutaneous dosing for 12 months)
Study: 25010820
Drug: Hemodynamic protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodynamic protocol including fluid administration and vasoactive drugs based on arterial blood pressure, cardiac index, and stroke volume response
Study: 19143532
Drug: Ribavirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (10 mg/kg per day in 4 divided doses for 7 days)
Study: 9240884
Drug: Bolus delivery
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus delivery of Curosurf (200 mg kg(‐1))
Study: 9240884
Drug: Side-hole delivery
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side-hole delivery of Curosurf (200 mg kg(‐1))
Study: 8275903
Drug: Naltrexone 1
Normalized name: NALTREXONE 1.5MG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 1 mg/kg/day
Study: 8275903
Drug: Naltrexone 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0.5, 1, and 2 mg/kg/day
Study: 3122164
Drug: Thyrotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin‐releasing hormone (TRH) administered intravenously
Study: 31273577
Drug: EGFR antibody-drug
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR antibody-drug conjugate (specific dosage and duration not mentioned)
Study: 22167145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressants (SSRIs) and cognitive behavioral therapy (CBT) for 6 weeks
Study: 22167145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressants (SSRIs) and cognitive behavioral therapy (CBT)
Study: 19780375
Drug: High-intensity respiratory
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity respiratory muscle training (RMT) performed daily at approximately 90% PI(max) for 6 weeks with 2 x 30 breath cycles using an Ultrabreathe lung trainer
Study: 15810603
Drug: Zhuyutongmai (ZYTM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuyutongmai (ZYTM) Capsule
Study: 11522557
Drug: Calcium load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium load of 0 and 25 mg/kg body weight taken at 0900 and 2100
Study: 11522557
Drug: Calcium load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium load of 0, 250, and 1000 mg taken at 0900
Study: 11522557
Drug: Calcium load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium load of 0 and 200 mg taken 4 times/day
Study: 11522557
Drug: Calcium loads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium loads of 0, 250, 1000 mg, and 200 mg taken at various times
Study: 1358168
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral tamoxifen (480 or 720 mg day‐1 for 6 days beginning 3 days before etoposide)
Study: 1358168
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (300 mg day‐1 for 3 days)
Study: 1358168
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral tamoxifen
Study: 6585909
Drug: Oxygen releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen releasing agent (two or four times a day for 1 week)
Study: 22017917
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g granular PGX®
Study: 22017917
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g granular PGX®
Study: 22017917
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g (inert fibre)
Study: 3938266
Drug: Cibenzoline (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (65 mg gelules, four times daily)
Study: 3938266
Drug: Quinidine arabo-galactane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine arabo-galactane sulfate (QAGS, 206 mg gelules, four times daily)
Study: 21284407
Drug: BMV 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMV 0.1% cream
Study: 9334595
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (0.075 mg) combined with papaverine hydrochloride (50 mg), prostaglandin E1 (10 micrograms), and phentolamine mesylate (0.2 mg)
Study: 9334595
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of papaverine hydrochloride (50 mg), prostaglandin E1 (10 micrograms), and phentolamine mesylate (0.2 mg) without atropine sulfate
Study: 8466313
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 24 IU for 5 days
Study: 27930531
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (1 mg/kg bolus, 60 μg/kg/h continuous infusion)
Study: 20968198
Drug: Cerebrolysin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (50 mL i.v. per day for 10 days)
Study: 12208031
Drug: 5-aminolaevulinic acid-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolaevulinic acid-induced photodynamic therapy (ALA-PDT)
Study: 8737704
Drug: Subconjunctival methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival methylprednisolone hemisuccinate (MH) 40 mg in 0.5 cc
Study: 7757308
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg t.i.d.)
Study: 6994782
Drug: Guanfacine (3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (3-4 mg daily)
Study: 6994782
Drug: Clonidine (0.3-0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3-0.45 mg daily)
Study: 30264164
Drug: Bacillus coagulans
Normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus coagulans LBSC [2 billion/g]
Study: 23358470
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg PO (days 1-21) and gemcitabine 1,000 mg/m² IV (days 1, 8, and 15) each 28-day cycle
Study: 21316768
Drug: Short-term therapies
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapies
Study: 19584651
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant tissue plasminogen activator (rt-PA) 50 mg with concomitant intravenous heparinization
Study: 10078083
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ibutilide
Study: 10078083
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ibutilide
Study: 10078083
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg DL-sotalol
Study: 2514457
Drug: Two puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Volumatic spacer
Study: 2514457
Drug: Two puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Nebuhaler spacer
Study: 2514457
Drug: Two puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through InspirEase spacer
Study: 2514457
Drug: Two puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Synchron‐Aerosol spacer
Study: 30047216
Drug: Liraglutide, Dulaglutide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide, Dulaglutide, Exenatide extended-release
Study: 28329368
Drug: Daily TMP-SMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP)
Study: 28329368
Drug: Daily TMP-SMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TMP-SMX alone
Study: 7201809
Drug: Niludipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine (60 or 120 mg daily for five consecutive weeks, with an initial dose of 20 mg three times on the first day)
Study: 7201809
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for one week after the drug period)
Study: 7201809
Drug: Niludipine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine (single dose study)
Study: 25899566
Drug: Sphenopalatine ganglion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sphenopalatine ganglion stimulation with one acupuncture needle for 4 weeks (once or twice weekly, total four to eight sessions)
Study: 25899566
Drug: Individualized verum
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized verum acupuncture for 4 weeks (twice weekly, total eight sessions)
Study: 23016126
Drug: Pre-exercise hyperhydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise hyperhydration (PEH) with 26 mL/kg bodyweight of a 130 mmol/L sodium solution
Study: 19095343
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronised 17beta‐oestradiol plus 5 mg dydrogesterone (E/D group; n=18)
Study: 19095343
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n=14)
Study: 19095343
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group; n=16)
Study: 9503255
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg +/- pindolol
Study: 9503255
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg +/- pindolol and 10 mg ipsapirone
Study: 7709763
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (100 U on alternate days) + oral calcium (1500 mg daily)
Study: 3108346
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (intracoronary streptokinase)
Study: 29605108
Drug: Routine MRI
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine MRI preparation (appointment letter)
Study: 22129475
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering treatment (Systolic BP≤140mmHg within 1 hour)
Study: 22129475
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment strategy (target systolic BP of 180mmHg)
Study: 14975534
Drug: Biventricular pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular pacing (cardiac resynchronisation therapy or CRT)
Study: 7919941
Drug: Haloperidol doses
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol doses of 40-45 mg/day
Study: 7919941
Drug: Haloperidol doses
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol doses of 60-80 mg/day